[Aromatase inhibitors in the adjuvant therapy of breast cancer].
Breast cancer is a hormone-sensitive cancer and in most post-menopausal women hormone receptor positive. The hormone receptor status is a highly valid predictive marker of responsiveness to endocrine therapy. The standard adjuvant therapy in patients with hormone-receptor-positive breast cancer is the selective estrogen receptor modulator tamoxifen. Third-generation aromatase inhibitors are accepted as a treatment option for metastatic breast cancer. However, results from recent studies show also a benefit of this type of drugs for disease-free survival with fewer adverse reactions in the adjuvant therapy. Therefore a new therapeutic field opens for the use of 3rd-generation aromatase inhibitors. This will lead to an expansion of the indication, but the question of modality -- up-front, switch or extended therapy -- remains to be resolved.
Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland.
D
D
Bauerschlag
C
C
Schem
N
N
Maass
W
W
Jonat
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen